Compugen (NASDAQ:CGEN – Get Free Report) and AquaBounty Technologies (NASDAQ:AQB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Volatility and Risk
Compugen has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
Valuation and Earnings
This table compares Compugen and AquaBounty Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $72.76 million | 3.09 | $35.34 million | $0.37 | 6.43 |
| AquaBounty Technologies | $2.47 million | 1.88 | -$18.49 million | ($1.19) | -0.76 |
Compugen has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Compugen and AquaBounty Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | 47.97% | 47.72% | 27.51% |
| AquaBounty Technologies | N/A | -54.51% | -16.67% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Compugen and AquaBounty Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 1 | 0 | 3 | 1 | 2.80 |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
Compugen presently has a consensus target price of $5.00, suggesting a potential upside of 110.08%. Given Compugen’s stronger consensus rating and higher probable upside, equities analysts plainly believe Compugen is more favorable than AquaBounty Technologies.
Insider and Institutional Ownership
12.2% of Compugen shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Compugen beats AquaBounty Technologies on 15 of the 15 factors compared between the two stocks.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
